Altered CD4 /CD8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis Altered CD4 /CD8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis2018-01-17T17:04:28-05:00
Therapy with glatiramer acetate for multiple sclerosis Therapy with glatiramer acetate for multiple sclerosis2018-01-17T17:04:23-05:00
Treatment of Multiple Sclerosis with the Pregnancy Hormone Estriol Treatment of Multiple Sclerosis with the Pregnancy Hormone Estriol2018-01-17T17:04:23-05:00
Economic evaluation of Avonex† (interferon beta-1a) in patients following a single demyelinating event Economic evaluation of Avonex† (interferon beta-1a) in patients following a single demyelinating event2018-01-17T17:04:16-05:00
Immunomodulation Of Autoimmune And Inflammatory Diseases With Intravenous Immune Globulin Immunomodulation Of Autoimmune And Inflammatory Diseases With Intravenous Immune Globulin2018-01-17T17:04:16-05:00
Treatment of severe autoimmune disease by stem-cell transplantation Treatment of severe autoimmune disease by stem-cell transplantation2018-01-17T17:04:11-05:00
Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis2018-01-17T17:03:58-05:00
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial2018-01-17T17:03:58-05:00